Patricia L. Novak
Corporate Officer/Principal at University of California, Irvine
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Julie Hill | F | 78 |
University of California, Irvine
| - |
Michael O'Reilly | M | 70 |
University of California, Irvine
| 16 years |
Arthur Palisoc | M | - |
University of California, Irvine
| - |
Howard Federoff | M | 71 |
University of California, Irvine
| - |
Mia Kyricos | F | - |
University of California, Irvine
| - |
Chen Li | M | - |
University of California, Irvine
| - |
Myles Baker | M | - |
University of California, Irvine
| - |
Susan Doniz | F | 54 |
University of California, Irvine
| - |
Andrew Yeiser | M | 98 |
University of California, Irvine
| - |
Maria Q. Feng | M | - |
University of California, Irvine
| - |
Marjan Farid | M | 50 |
University of California, Irvine
| 15 years |
Michael S. Robb | M | 76 |
University of California, Irvine
| - |
Kerry Vandell | M | 77 |
University of California, Irvine
| 7 years |
Jody L. Errandi | F | - |
University of California, Irvine
| - |
Peter N. R. Heseltine | M | - |
University of California, Irvine
| - |
Stephen Runnels | M | - |
University of California, Irvine
| - |
Yong Chen | M | 63 |
University of California, Irvine
| 31 years |
Kaushal Agrawal | M | - |
University of California, Irvine
| 2 years |
Tom N. Cornsweet | M | - |
University of California, Irvine
| - |
Assad Kazeminy | M | 73 |
University of California, Irvine
| - |
Carolyn Canning-White | F | - |
University of California, Irvine
| - |
Erich Delcamp | M | - |
University of California, Irvine
| - |
Kirsten Quanbeck | F | - |
University of California, Irvine
| - |
Tony Hwang | M | - |
University of California, Irvine
| - |
Michelle Quint | F | - |
University of California, Irvine
| - |
Harvey Shieh | M | - |
University of California, Irvine
| - |
Dawn McKinley | F | - |
University of California, Irvine
| - |
Katherine Hills | F | - |
University of California, Irvine
| - |
Tracey Kincaid | F | - |
University of California, Irvine
| - |
Michelle Hererra | F | - |
University of California, Irvine
| - |
Annie Le | F | - |
University of California, Irvine
| - |
Vivian U. | F | - |
University of California, Irvine
| - |
Darlene Esparza | F | - |
University of California, Irvine
| - |
Patrick J. Walsh | M | - |
University of California, Irvine
| - |
Richard H. Lathrop | M | - |
University of California, Irvine
| - |
Jeffrey Margolis | M | 60 |
University of California, Irvine
| - |
Gary S. Lynch | M | 80 |
University of California, Irvine
| 55 years |
G. Scott Samuelsen | M | 81 |
University of California, Irvine
| 54 years |
Tim Stanley | M | 57 |
University of California, Irvine
| - |
James R. Mellor | M | 92 |
University of California, Irvine
| - |
Donald R. Beall | M | 85 |
University of California, Irvine
| - |
Don Bailey | M | 78 |
University of California, Irvine
| - |
Christopher Callero | M | 72 |
University of California, Irvine
| - |
Roger K. Freeman | M | 88 |
University of California, Irvine
| - |
James V. Mazzo | M | 66 |
University of California, Irvine
| - |
Ronald H. Wender | M | 77 |
University of California, Irvine
| - |
Noel J. Cusack | M | - |
University of California, Irvine
| - |
Carl Cotman | M | 84 |
University of California, Irvine
| 56 years |
Shu Li | M | 65 |
University of California, Irvine
| - |
Patrick Walsh | M | 63 |
University of California, Irvine
| - |
Rick Dutta | M | - |
University of California, Irvine
| - |
M. Cass Wheeler | M | - |
University of California, Irvine
| - |
Peter John Burke | M | - |
University of California, Irvine
| - |
Glen E. Schrank | M | 68 |
University of California, Irvine
| - |
Jeffrey J. Katke | M | - |
University of California, Irvine
| - |
Shankar Basu | M | - |
University of California, Irvine
| - |
Clarence W. Barker | M | - |
University of California, Irvine
| - |
Barry D. Pressman | M | 79 |
University of California, Irvine
| - |
Richard Granger | M | - |
University of California, Irvine
| - |
Chun Ki Hong | M | 63 |
University of California, Irvine
| - |
Steven Barker | M | 79 |
University of California, Irvine
| 34 years |
Bill Shopoff | M | 66 |
University of California, Irvine
| - |
David Kim | M | - |
University of California, Irvine
| - |
Adriana Romero | F | - |
University of California, Irvine
| - |
Gregory D. Vacca | M | 74 |
University of California, Irvine
| - |
Vicken Karageozian | M | - |
University of California, Irvine
| - |
Vicki Clements | F | - |
University of California, Irvine
| - |
Marcela Ramirez-Stapleton | F | - |
University of California, Irvine
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christopher Reinhard | M | 70 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 6 years |
John Sayward | M | 73 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 5 years |
Anthony Andrasfay | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA.
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million.
Cardium Therapeutics, Inc. /Old/
| 9 years |
Robert Engler | M | 79 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 5 years |
David C. Dreyer | M | 67 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 7 years |
Michael Cannon | M | 78 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 7 years |
Harry E. Gruber | M | 72 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 10 years |
Cleland C. Landolt | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 6 years |
Ted Williams | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 3 years |
Bonnie Ortega | F | - |
Cardium Therapeutics, Inc. /Old/
| 1 years |
Ted William | M | - |
Cardium Therapeutics, Inc. /Old/
| - |
Tyle M. Dylan-Hyde | M | 62 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 4 years |
Juliet Singh | M | 64 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 2 years |
Mark D. Erion | M | 66 |
SICOR, Inc.
SICOR, Inc. Pharmaceuticals: MajorHealth Technology Part of Teva Pharmaceutical Industries Ltd., SICOR, Inc. is a company that manufactures pharmaceuticals. The company is based in San Diego, CA. The company was founded by Harry E. Gruber, Jack W. Reich, Paul K. Laikind, Robert L. Engler. SICOR was acquired by Teva Pharmaceutical Industries Ltd. on January 22, 2004 for $3,297.10 million. | 5 years |
Ronald Simon | M | 85 |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 4 years |
Jack Lief | M | 78 |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | 6 years |
Dale A. Stringfellow | M | - |
Collateral Therapeutics, Inc.
Collateral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Collateral Therapeutics, Inc. focuses on the discovery and development of non-surgical gene therapy product candidates for the potential treatment of cardiovascular diseases including: coronary artery disease; peripheral vascular disease; restenosis; congestive heart failure and heart attack. The company's core technology is centered on methods of cardiovascular gene therapy; a portfolio of therapeutic genes and gene delivery vectors. Its portfolio includes human genes in the Fibroblast Growth Factor (FGF) and Vascular Endothelial Growth Factor (VEGF) gene families to be used in investigational gene therapy product candidates. The company is headquartered in San Diego, CA. | 5 years |
Paul F. Glidden | M | - |
Alpha Therapeutic Corp.
Alpha Therapeutic Corp. BiotechnologyHealth Technology Part of Grifols SA/Grifols Family/, Alpha Therapeutic Corp. develops plasma derived products. The company is based in Los Angeles, CA. | 11 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 86 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Patricia L. Novak
- Personal Network